Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Portage Biotech Inc. (PRTG)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
19.52-0.30 (-1.51%)
At close: 4:00PM EDT
19.52 0.00 (0.00%)
After hours: 04:36PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Portage Biotech Announces Participation in September 2021 Investor Conferences

    WESTPORT, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that as part of its commitment to investor outreach, management will be participating in the following investor conferences in September 2021. H.C. Wainwright 23rd Annual Global Investor ConferenceDate: September 13, 2021Format: Co

  • GlobeNewswire

    Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year

    - $29 million raised during quarter with broad institutional support - Proceeds will accelerate advancement of clinical pipeline toward multiple data readouts over the next 18-24 months WESTPORT, Conn., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced financial results for the quarter ended June 30

  • GlobeNewswire

    Portage Biotech Issues Letter to Shareholders

    WESTPORT, Conn., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today issued the following letter to shareholders: Dear Shareholders, On behalf of the team at Portage Biotech, Inc., I am pleased to provide you with a corporate update, reflecting on the progress that we have made throughout the first half of 2021 and the found

Advertisement
Advertisement